BA
TEVA icon

BlackRock Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-125,000
Closed -$6.69M – 3802
2016
Q1 		$6.69M Buy
+125,000
New +$7.33M 0.01% 972

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

BlackRock Advisors's TEVA Position: Q4 2016 in Review

BlackRock Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 71% in Q4 2016, selling an estimated $186M and leaving 1,888,452 shares worth $68.5M. The position accounts for 0.07% of the portfolio, ranked #264.

BlackRock Advisors first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $617M in Q2 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • BlackRock Advisors held 1,888,452 shares of Teva Pharmaceuticals worth $68.5M as of Q4 2016.
  • BlackRock Advisors sold 4,652,768 Teva Pharmaceuticals shares in Q4 2016, an estimated $186M.
  • Teva Pharmaceuticals made up 0.07% of BlackRock Advisors's portfolio in Q4 2016, its #264 holding.
  • BlackRock Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Teva Pharmaceuticals position peaked at $617M in Q2 2015.
  • 737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.